Private company

Global Blood Therapeutics, Inc.

American pharmaceutical preparations company based in South San Francisco2

In its 2022 annual report the company says: “We are a biopharmaceutical company driven by our mission to discover, develop and deliver life-changing treatments that provide hope to underserved patient communities, starting with sickle cell disease, or SCD.”64

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersSouth San Francisco, United States2
  • Incorporated inDE3
  • Business address181 Oyster Point Blvd, South San Francisco, Ca 940803
  • Filer categoryLarge accelerated filer3
  • Legal formCorporation2
  • LEI549300U4G0QKK99GRT152
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O UNITED AGENT GROUP INC., 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 49361822

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-147.7%Operating margin4
-155.6%Net margin4
57.3%Revenue growth, 20214
-154.3%Return on equity4
1.25×Debt to equity4
-$260.0MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue1¢$3.3M
  • Research and development44¢$212.1M
  • Selling, general and admin55¢$267.0M
  • Income tax0¢$477.0K

Out of $194.7M in revenue.4 The company lost money this year.

Financial statements

Revenue4$194.7M in 2021+9139% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $2.1M$2.1M20192020: $123.8M$123.8M2020+5773%2021: $194.7M$194.7M2021+57%
Operating income56784-$287.7M in 2021+520% since 2015
-$300.0M-$200.0M-$100.0M02015: -$46.4M-$46.4M20152016: -$83.1M-$83.1M2016+79%2017: -$119.2M-$119.2M2017+43%2018: -$182.7M-$182.7M2018+53%2019: -$281.3M-$281.3M2019+54%2020: -$243.2M-$243.2M2020−14%2021: -$287.7M-$287.7M2021+18%
Net income56784-$303.1M in 2021+554% since 2015
-$400.0M-$300.0M-$200.0M-$100.0M02015: -$46.4M-$46.4M20152016: -$82.5M-$82.5M2016+78%2017: -$117.0M-$117.0M2017+42%2018: -$174.2M-$174.2M2018+49%2019: -$266.8M-$266.8M2019+53%2020: -$247.6M-$247.6M2020−7%2021: -$303.1M-$303.1M2021+22%
Fiscal year2015201620172018201920202021
Revenue$2.1M4$123.8M4$194.7M4
Cost of revenue$48.0K4$2.0M4$3.3M4
Research and development$36.7M5$62.2M6$87.8M7$131.3M8$174.6M4$155.1M4$212.1M4
Selling, general and admin$31.4M7$51.4M8$117.1M4$210.9M4$267.0M4
Operating expenses$482.4M4
Operating income-$46.4M5-$83.1M6-$119.2M7-$182.7M8-$281.3M4-$243.2M4-$287.7M4
Income before tax-$302.6M4
Income tax$06$06$07$08$4.0K4$04$477.0K4
Net income-$46.4M5-$82.5M6-$117.0M7-$174.2M8-$266.8M4-$247.6M4-$303.1M4

Compare Global Blood Therapeutics, Inc. with another company

Corporate structure

Global Blood Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Global Blood Therapeutics, Inc.

  • Deep Track Capital, LP Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 14, 2023 (2 filings since Jun 17, 2022)
  • FMR LLC Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 9, 2023 (2 filings since Feb 9, 2022)
  • BAKER BROS. ADVISORS LP Filed SC 13G on Global Blood Therapeutics, Inc., latest Feb 14, 2022
  • PERCEPTIVE ADVISORS LLC Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 14, 2022
  • PRICE T ROWE ASSOCIATES INC /MD/ Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 14, 2022
  • Point72 Asset Management, L.P. Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 14, 2022
  • Janus Henderson Group Ltd. Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 10, 2022 (2 filings since Oct 12, 2021)
  • VANGUARD GROUP INC Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Feb 10, 2022
  • Bank of America Filed SC 13G/A on Global Blood Therapeutics, Inc., latest Jan 31, 2022
  • Global Blood Therapeutics, Inc. South San Francisco, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Global Blood Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$50.4M4 Dec 31, 2021$47.7M4 Dec 31, 2020+5.6%
Accumulated depreciation$15.5M4 Dec 31, 2021$9.9M4 Dec 31, 2020+57.3%
Property and equipment, net$34.9M4 Dec 31, 2021$37.9M4 Dec 31, 2020−7.8%
Operating-lease assets (leased space)$48.0M4 Dec 31, 2021$50.7M4 Dec 31, 2020−5.3%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$684.7M4 Dec 31, 2021$494.8M4 Dec 31, 2020+38.4%
Marketable securities, current$04 Dec 31, 2021$66.1M4 Dec 31, 2020−100.0%
Marketable securities, non-current$50.1M4 Dec 31, 2021$04 Dec 31, 2020
Debt securities available for sale$721.9M4 Dec 31, 2021$552.3M4 Dec 31, 2020+30.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$58.2M4 Dec 31, 2021$40.2M4 Dec 31, 2020+44.7%
Raw materials$10.6M4 Dec 31, 2021$11.3M4 Dec 31, 2020−5.8%
Work in process$45.7M4 Dec 31, 2021$27.0M4 Dec 31, 2020+69.2%
Finished goods$1.9M4 Dec 31, 2021$2.0M4 Dec 31, 2020−1.6%

Leadership

Who has led Global Blood Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Ted W. Love2016–2022

President

  1. Ted W. Love2016–2022

Chief financial officer

  1. Jeffrey S. Farrow2016–2022
20202025
Board members and other officers (26)

Timeline

  1. Oct 5, 20228-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale40
  2. Sep 30, 20228-K Shareholder vote; Other events41
  3. Sep 23, 20228-K Other events42
  4. Aug 8, 20228-K Entered a material agreement; Bylaws or fiscal year changed; Other events43
  5. Jul 26, 20228-K Other events44
  6. Jul 14, 20228-K Other events45
  7. Jun 29, 20228-K Other events46
  8. Jun 15, 20228-K Shareholder vote47
  9. Jun 13, 20228-K Other events48
  10. Jun 10, 20228-K Other events49
  11. Jun 6, 20228-K Other events50
  12. May 12, 20228-K Other events51
  13. Feb 3, 2016New chief executive Ted W. Love becomes CEO13

Calendar

When it reported results

  1. May 4, 2022Reported quarterly or annual results52
  2. Feb 23, 2022Reported quarterly or annual results53
  3. Nov 4, 2021Reported quarterly or annual results54

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

140 filings to the SEC since October 2021: 1 annual reports, 3 quarterly reports, 27 major events, 67 insider forms, 12 large holders, 30 other. The latest 20:

  1. Feb 14, 2023SC 13G/A EDGAR
  2. Feb 9, 2023SC 13G/A EDGAR
  3. Oct 17, 202215-12G EDGAR
  4. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  5. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  6. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  7. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  8. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  9. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  10. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  11. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  12. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  13. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  14. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  15. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  16. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  17. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  18. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  19. Oct 6, 20224 FORM 4 SUBMISSION EDGAR
  20. Oct 5, 2022S-8 POS EDGAR

The 140 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

4 open-market trades by officers, directors and large owners since October 2021: 0 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 1, 2022Farrow Jeffrey SChief Financial OfficerSale31,441$68.00$2.1MForm 4
Aug 18, 2022Habibizad NazilaSee RemarksSale4,678$67.19$314.3KForm 4
Jun 21, 2022Pizzo Philip A.DirectorSale1,260$27.25$34.3KForm 4
Jun 21, 2022Svoronos DawnDirectorSale1,908$27.24$52.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Global Blood Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGlobal Blood Therapeutics, Inc.1
  • CIK0001629137
  • Employer ID (EIN)27-48257121
  • Filer statusLarge accelerated filer1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address181 Oyster Point Blvd, South San Francisco, CA 940801
  • Phone650741-77001
  • Shares outstanding67,463,704 as of Aug 4, 202210
  • Public float$888.3M as of Jun 30, 20214
  • On EDGAR sinceJan 5, 20151
  • Filings736 in all: 4 (361), 8-K (133), SC 13G/A (41), 3 (31), DEFA14A (23), 10-Q (22), SC 13G (18), 5 (12)1
    All 38 form types

    4/A (11), S-8 (11), S-8 POS (11), 424B5 (10), 10-K (7), DEF 14A (7), CORRESP (4), EFFECT (3), POSASR (3), 3/A (2), 424B4 (2), DRSLTR (2), S-1 (2), S-1/A (2), S-3ASR (2), UPLOAD (2), 10-Q/A (1), 15-12G (1), 25-NSE (1), 5/A (1), 8-A12B (1), CERTNAS (1), CT ORDER (1), D (1), DEFM14A (1), DRS (1), DRS/A (1), PREM14A (1), S-1MEF (1), S-3 (1)

  • Latest filingsAnnual report (10-K) Feb 23, 2022
    Quarterly report (10-Q) Aug 8, 2022
    Proxy statement (DEF 14A) Apr 28, 2022
    Latest 8-K (8-K) Oct 5, 2022

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
    SEC EDGAROther events
  43. 43
  44. 44
    SEC EDGAROther events
  45. 45
    SEC EDGAROther events
  46. 46
    SEC EDGAROther events
  47. 47
  48. 48
    SEC EDGAROther events
  49. 49
    SEC EDGAROther events
  50. 50
    SEC EDGAROther events
  51. 51
    SEC EDGAROther events
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64